Institute for Molecular Cardiovascular Research, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Institute for Molecular Cardiovascular Research, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, Maastricht, the Netherlands.
Mol Aspects Med. 2022 Aug;86:101010. doi: 10.1016/j.mam.2021.101010. Epub 2021 Aug 14.
Despite the introduction of lipid-lowering drugs, antihypertensives, antiplatelet and anticoagulation therapies for primary prevention of cardiovascular and heart diseases (CVD), it remains the number one cause of death globally, raising the question for novel/further essential factors besides traditional risk factors such as cholesterol, blood pressure and coagulation. With continuous identification and characterization of non-enzymatic post-translationally modified isoforms of proteins and lipoproteins, it is becoming increasingly clear that irreversible non-enzymatic post-translational modifications (nPTMs) alter the biological functions of native proteins and lipoproteins thereby transforming innate serum components into CVD mediators. In particular renal insufficiency and metabolic imbalance are major contributors to the systemically increased concentration of reactive metabolites and thus increased frequency of nPTMs, promoting multi-morbid disease development centering around cardiovascular disease. nPTMs are significantly involved in the onset and progression of cardiovascular disease and represent a significant and novel risk factor. These insights represent potentially new avenues for risk assessment, prevention and therapy. This review chapter summarizes all forms of nPTMs found in CKD and under metabolic imbalance and discusses the biochemical connections between molecular alterations and the pathological impact on increased cardiovascular risk, novel nPTM-associated non-traditional cardiovascular risk factors, and clinical implication of nPTM in cardiovascular disease.
尽管降脂药物、抗高血压药物、抗血小板和抗凝治疗已被用于心血管疾病(CVD)的一级预防,但它仍然是全球头号死因,这引发了一个问题,除了胆固醇、血压和凝血等传统危险因素外,是否还存在其他新的/必要的因素。随着对蛋白质和脂蛋白的非酶翻译后修饰同工型的不断识别和特征描述,越来越明显的是,不可逆的非酶翻译后修饰(nPTMs)改变了天然蛋白质和脂蛋白的生物学功能,从而将先天的血清成分转化为 CVD 介质。特别是肾功能不全和代谢失衡是导致反应性代谢物浓度在体内系统性增加的主要原因,从而增加 nPTMs 的频率,促进以心血管疾病为中心的多种疾病的发展。nPTMs 显著参与了心血管疾病的发生和发展,是一个重要的新的危险因素。这些新的认识为风险评估、预防和治疗提供了新的途径。这篇综述章节总结了在 CKD 和代谢失衡下发现的所有形式的 nPTMs,并讨论了分子改变与增加心血管风险的病理影响之间的生化联系、新型 nPTM 相关非传统心血管危险因素,以及 nPTM 在心血管疾病中的临床意义。